Immutep (IMMP) Earnings Date & Reports

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

IMMP is expected to report earnings to rise 694.00% to -15 cents per share on September 02

Q2'26

Est.

$-0.16

Q4'24

Beat

by $0.12

Q4'23

Missed

by $0.05

Q2'23

Est.

$-0.15

Q4'22

Beat

by $0.01

The last earnings report on February 26 showed earnings per share of -1 cents, beating the estimate of -14 cents. With 419.79K shares outstanding, the current market capitalization sits at 48.78M.

View a ticker or compare two or three

Compare

IMMP

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for IMMP